MedPath

Mycophenolic acid

Generic Name
Mycophenolic acid
Brand Names
Myfortic
Drug Type
Small Molecule
Chemical Formula
C17H20O6
CAS Number
24280-93-1
Unique Ingredient Identifier
HU9DX48N0T
Background

Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative azathioprine due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity. Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. Mycophenolate mofetil, a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection.

Indication

Mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. Mycophenolic acid is used in combination with cyclosporine and corticosteroids.

Associated Conditions
Kidney Transplant Rejection

Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP

Phase 4
Conditions
Immune Thrombocytopenia
Interventions
First Posted Date
2019-06-26
Last Posted Date
2021-06-11
Lead Sponsor
Shandong University
Target Recruit Count
30
Registration Number
NCT03998982
Locations
🇨🇳

Qilu hospital, Shandong University, Jinan, Shandong, China

Standard- Versus Reduced-dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Renal Transplantation

Phase 4
Completed
Conditions
Disorder Related to Renal Transplantation
Interventions
First Posted Date
2019-05-30
Last Posted Date
2019-05-30
Lead Sponsor
Ajou University School of Medicine
Target Recruit Count
108
Registration Number
NCT03968588
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

🇰🇷

Ajou University Hospital, Suwon, Korea, Republic of

🇰🇷

Gangnam Severance Hospital, Seoul, Korea, Republic of

and more 1 locations

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Phase 1
Active, not recruiting
Conditions
Hematologic Diseases
Chronic Myelogenous Leukemia, Accelerated Phase
Myelodysplastic Syndromes
Mantle Cell Lymphoma
Follicular Lymphoma
Diffuse Large B Cell Lymphoma
Graft Vs Host Disease
Acute Leukemia in Remission
Chronic Myelogenous Leukemia, Blastic Phase
Non Hodgkin Lymphoma
Interventions
First Posted Date
2019-02-15
Last Posted Date
2025-04-08
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
43
Registration Number
NCT03842696
Locations
🇺🇸

University of Colorado, Aurora, Colorado, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

and more 4 locations

RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients

Phase 4
Active, not recruiting
Conditions
Renal Transplant Recipients
Elderly Patients
Immunosuppression
Interventions
Drug: low dose tacrolimus in combination with everolimus
First Posted Date
2019-01-09
Last Posted Date
2023-05-10
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
374
Registration Number
NCT03797196
Locations
🇳🇱

LUMC, Leiden, Netherlands

🇳🇱

UMCU, Utrecht, Netherlands

🇧🇪

Leuven University Hospital, Leuven, Belgium

and more 4 locations

Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome

Phase 4
Completed
Conditions
Kidney Transplant
Interventions
First Posted Date
2019-01-07
Last Posted Date
2024-05-22
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
169
Registration Number
NCT03794492
Locations
🇰🇷

Ajou University Hospital, Suwan, Korea, Republic of

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
Chronic Lymphocytic Leukemia
T-cell Lymphoma
Acute Myeloid Leukemia
B-cell Lymphoma
Hodgkin Lymphoma
Chronic Myelomonocytic Leukemia
Myeloproliferative Disorder
Non Hodgkin Lymphoma
Interventions
Radiation: Total body irradiation (TBI)
Drug: Anti-thymocyte globulin (ATG)
Radiation: Total lymphoid irradiation (TLI)
First Posted Date
2018-11-08
Last Posted Date
2023-12-12
Lead Sponsor
Stanford University
Target Recruit Count
22
Registration Number
NCT03734601
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Mycophenolate Mofetil Pharmacokinetics in Systemic Sclerosis

Completed
Conditions
Systemic Sclerosis
Gastrointestinal Complication
Interventions
Diagnostic Test: P-MPA concentration
First Posted Date
2018-09-20
Last Posted Date
2020-03-13
Lead Sponsor
Region Skane
Target Recruit Count
35
Registration Number
NCT03678987
Locations
🇸🇪

Reumatologi SUS Lund, Region Skåne, Lund, Sweden

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Phase 2
Active, not recruiting
Conditions
Acute Lymphocytic Leukemia
Relapsed Large Cell Lymphoma
Mantle Cell Lymphoma
Acute Myeloid Leukemia
Myelodysplasia
Burkitt Lymphoma
Hodgkin Lymphoma
Relapsed T-Cell Lymphoma
Biphenotypic/Undifferentiated Leukemia
Lymphoplasmacytic Lymphoma
Interventions
Drug: Total Body Irradiation (TBI)
Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
Drug: MGTA 456 Infusion
First Posted Date
2018-09-17
Last Posted Date
2024-04-10
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
22
Registration Number
NCT03674411
Locations
🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)

Phase 2
Conditions
Lupus Nephritis
Interventions
Other: Mesenchymal stem cells
Other: Placebo of Mesenchymal stem cells
First Posted Date
2018-07-09
Last Posted Date
2018-07-10
Lead Sponsor
Lingyun Sun
Target Recruit Count
230
Registration Number
NCT03580291
Locations
🇨🇳

The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Tolerance by Engaging Antigen During Cellular Homeostasis

Phase 1
Active, not recruiting
Conditions
Renal Transplantation
Renal Transplant Recipient
Kidney Transplantation
Interventions
First Posted Date
2018-04-20
Last Posted Date
2025-02-21
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
8
Registration Number
NCT03504241
Locations
🇺🇸

Duke University Health System, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath